Curis, Inc.
1.590.02 (1.27%)

After hours: 1.590.00 (0.00%) as of 4:44 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.57
Bid1.24 x 100
Ask3.99 x 100
52wk Range1.25 - 3.28
Day's Range1.57 - 1.62
Avg Vol (3m)405,966
As of 4:00 PM EDT. Market closed.
  • Capital Cube6 days ago

    ETF’s with exposure to Curis, Inc. : July 19, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Curis, Inc.Here are 5 ETF’s with the largest exposure to CRIS-US. Comparing the performance and risk of Curis, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns […] (Read more...) The post ETF’s with exposure to Curis, Inc. : July 19, 2016 appeared first on CapitalCube.

  • American City Business Journalslast month

    What’s so ‘groundbreaking’ about Curis’ new cancer drug that just began human trials?

    The field of so-called immuno-oncology drugs — those that enhance the immune system’s ability to fight cancer — has been a noisy one lately, with dozens of companies aiming to develop them after the U.S. approval of the first two in 2014. Opdivo, the Bristol-Meyer Squibb (BMY) drug for melanoma, lung and renal cancer, is expected to generate about $2.8 billion this year. Both are fruition of years of research into a new way of fighting cancer that’s intended to enhance existing cancer drugs.